Roche and BioLamina Collaborate on Novel Cell Culture Systems
Roche and BioLamina have entered into a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will assess laminin-based in-vitro cell culture matrices that can offer physiological microenvironments for living cells.
Roche and BioLamina have entered into a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will assess laminin-based in vitro cell culture matrices that can offer physiological microenvironments for living cells. Roche will provide R&D funding and scientific expertise to BioLamina. Financial details of the agreement were not disclosed.
Laminins are proteins located in the extracellular matrix with specific tissue distribution. They are essential for cell growth and behaviour, making them an interesting target for new biologically relevant cell culturing techniques. Laminins can be exploited to solve the technical problems in stem cell culture. For example, it has been discovered that coating the cell culture dishes with biologically relevant human recombinant laminins offers physiological microenvironments to primary cells, including stem cells. When these cells feel at home under such conditions, they do not change their phenotype, which is important for in vitro studies. In principle, the use of laminins allows infinite culture of stem cells and other primary cell types to remain in completely defined environments in vitro. These proteins could potentially solve issues of repeatability as well as undefined and complex culture systems, making biological research and development easier and more reliable, with faster clinical applications.
"Our aim is to develop laminin-based culture systems that provide biologically relevant, standardized environments," said Ruedi Stoffel, head of biochemical reagents & custom biotech at Roche in a press statement. "We are looking forward to this collaboration to build on the revolutionary cell cultivation techniques developed by our colleagues at the Karolinska Institute and BioLamina."
"We're delighted that Roche has recognized the potential of our products and technology, which we believe will significantly complement their expertise and capabilities in cell culturing," commented Kristian Tryggvason, CEO of BioLamina. "By resolving many of the technical obstacles currently blocking the road to modern cell therapy, we expect this collaboration to accelerate the development of innovative cell culturing solutions that possibly can enable cell therapy."
BioLamina commercializes innovations based on recombinant laminins developed by Professor Karl Tryggvason at the Karolinska Institute. The company has been producing laminins for different cell types.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
